| Abstract [eng] |
The Study of the Molecular Biomarkers for the Identification of Clinically Significant Prostate Cancer The aim of the study: to evaluate the significance of molecular biomarkers for the identification of clinically significant prostate cancer. Objectives: to determine the expression of CRISP3, LMTK2, MSMB genes in patients' blood and to evaluate the relationship with clinical – pathological characteristics; to determine the frequency of MSMB gene polymorphism in patients' blood and to evaluate the relationship with clinical – pathological characteristics; to compare the relationship between molecular biomarkers for the identification of clinically significant prostate cancer. The object of the study. 193 prostate cancer patients were involved in the study. All patients were hospitalized for the histological verification in the Oncourology Department of National Cancer Institute during the period of 2016 – 2018 for transperineal prostate biopsy. Peripheral blood remained after all mandatory blood tests were used for the research of molecular biomarkers. The control group consisted of 20 healthy male blood samples. Methods. A real-time polymerase chain reaction (RT-PCR) method was used to evaluate CRISP3, LMTK2 and MSMB genes expression level. Changes in gene expression were calculated using 2-ΔΔCT method. MSMB gene (-57 C/T) polymorphism was investigated using pyrosequencing method. Results. Significant correlation was found between CRISP3 expression in blood and serum PSA levels after transperineal prostate biopsy (p=0.016); between LMTK2 expression in blood and serum PSA levels before transperineal prostate biopsy (p=0.003). Statistically significant association was assessed between high CRISP3 and low MSMB expression in blood and serum PSA levels after biopsy (p=0.030); low LMTK2 and low MSMB expression in blood and serum PSA levels before prostate biopsy (p=0.048); MSMB expression in blood and MSMB (-57 C/T) polymorphism variants (p=0.009). Conclusions. High CRISP3 and low LMTK2 expression in blood are related to serum PSA concentration (p=0.016; p=0.003). MSMB (-57 C/T) polymorphism CT variant was more often identified for the patients with clinically insignificant prostate cancer, however, due to the T allele association with an increased risk of aggressive prostate cancer, for such patients active surveillance is recommended. Moreover, active surveillance must be used for the patients with clinically insignificant prostate cancer, who get into the poor prognosis group according to CRISP3, LMTK2 and MSMB expression in blood. |
